214601-54-4

Basic information

• Product Name: (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal
• Synonyms: (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal
• CAS NO: 214601-54-4
• Molecular Weight: 429.602
• Mol File: 214601-54-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal(214601-54-4)
• EPA Substance Registry System: (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal(214601-54-4)

Safety Data

• Hazardous Substances Data: 214601-54-4(Hazardous Substances Data)

Upstream product

• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 854306-68-6 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol 
• 124937-52-6 tolterodine tartrate 
• 100-44-7 benzyl chloride 
• 209747-05-7 (S)-2-[3-[bis-(1-methylethyl)-amino]-1-phenylpropyl]-4-methylphenol tartrate 
• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 1373556-77-4 N,N-diisopropyl-3-(2-benzyloxy-5-methyl-phenyl)-3-phenyl-propane amide 
• 854306-67-5 methyl 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionate 
• 106-44-5 p-cresol 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 140-10-3 (E)-3-phenylacrylic acid 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 

Downstream Products

• 214601-12-4 (R)-N,N-diisopropyl-3-phenyl-3-(5-formyl-2-hydroxyphenyl)propyl-1-amine 
• 250214-44-9 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxyl-methyl)phenyl isobutyrate 
• 1076199-77-3 racemic 3-(3-N,N'-diisopropylamino-1-phenyl-propyl)-4-hydroxy-benzoic acid 
• 1390644-39-9 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-formylphenyl methacrylate 
• 1390644-41-3 (R)-3-(3-(diisopropylamino)-1-phenylpropyl)-4-(methacryloyloxy)benzoic acid 
• 1390644-42-4 3-(3-(diisopropylamino)-1-phenylpropyl)-4-(methacryloyloxy)benzoic acid 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-02-7 fesoterodine 
• 286930-03-8 fesoterodine fumarate 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 
• 1309839-68-6 C₄₃H₅₇N₃O₅ 
• 1309839-66-4 C₄₅H₆₂N₄O₆S 
• 1309839-64-2 C₄₅H₆₁N₃O₅ 

Relevant articles and documents

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

DESFESOTERODINE SALTS

The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.